SEC Form 4 · accession 0001209191-16-108969
Cascadian Therapeutics, Inc. · CASC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher S Henney
Officer — Interim CEO and President · Director
Period of report
Mar 16, 2016
Accepted (ET)
Mar 16, 2016 · 8:37 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001412067
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $1.06 | Mar 16, 2016 | A | 150,000 | A | — | Mar 16, 2024 | Common Stock | 150,000 | 150,000 | D |
Explanation of responses
- F1The option vests and is exercisable at the rate of 1/6th of the total shares on each of February 11, 2016, March 11, 2016, April 11, 2016, May 11, 2016, June 11, 2016 and July 11, 2016, with 100% vested and exercisable on July 11, 2016, subject to the reporting person's provision of service to the Company on each vesting date; provided, however, that upon the occurrence of certain events the vesting of unvested shares shall be accelerated.